Stellungnahme – Früherkennung und frühe Behandlung sind entscheidend für die Senkung der Brustkrebssterblichkeit

Senologie 2011; 8 Die Bisphosphonate (BP) sind seit langem ein wichtiger Bestandteil in der Therapie des Mammakarzinoms. Die Substanzgruppe der BP gehört zu den Pyrophosphatderivaten und zeichnet sich durch eine hohe Affinität zum Knochen aus. Die Effekte der BP beruhen vor allem auf der Hemmung der überschießenden Osteoklastenaktivität, so dass das Gleichgewicht zwischen Knochenaufbau und -abbau wiederhergestellt und der pathologischen Zerstörung des Knochens entgegengewirkt wird. Darüber hinaus verhindern BP die osteoblastenvermittelte Osteoklastenaktivierung sowie die Entstehung von Osteoklasten aus ihren Vorläuferzellen.

[1]  L. Tabár,et al.  Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. , 2011, Radiology.

[2]  Philippe Autier,et al.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database , 2011, BMJ : British Medical Journal.

[3]  J. Hanley Measuring mortality reductions in cancer screening trials. , 2011, Epidemiologic reviews.

[4]  K. Aben,et al.  Declined Guideline Adherence in Older Breast Cancer Patients: A Population‐Based Study in The Netherlands , 2011, The breast journal.

[5]  Marvin Zelen,et al.  Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.

[6]  Guangyu Liu,et al.  Breast cancer in Chinese elderly women: pathological and clinical characteristics and factors influencing treatment patterns. , 2009, Critical reviews in oncology/hematology.

[7]  D. Schopper,et al.  How effective are breast cancer screening programmes by mammography? Review of the current evidence. , 2009, European journal of cancer.

[8]  M Kalder,et al.  Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Forbes,et al.  Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Winer,et al.  Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Vlastos,et al.  Older female cancer patients: importance, causes, and consequences of undertreatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Micciolo,et al.  Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. , 2006, Critical reviews in oncology/hematology.

[13]  E. Elkin,et al.  Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Goodwin,et al.  Use and outcomes of adjuvant chemotherapy in older women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Crowley,et al.  Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Hortobagyi,et al.  Breast cancer treatment guidelines in older women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Schraub,et al.  Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Paridaens,et al.  Taxanes in elderly breast cancer patients. , 2004, Cancer treatment reviews.

[19]  G. Vlastos,et al.  Undertreatment strongly decreases prognosis of breast cancer in elderly women. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Hendriks,et al.  Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review , 2003, The Lancet.

[21]  Xianglin L. Du,et al.  Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Tabár,et al.  The mammographic screening trials: Commentary on the recent work by Olsen and Gøtzsche , 2002, Journal of surgical oncology.

[23]  A. Miller Screening for breast cancer with mammography , 2001, The Lancet.

[24]  G. Hortobagyi,et al.  Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  F. Cavalli,et al.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Elledge,et al.  Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.

[27]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.